About Small Volume Injectable
Injectables or small-volume parenteral solutions (SVPs) are solutions having a volume of less than 100 mL (as specified by USP) that are designed for intermittent intravenous delivery (usually defined as an infusion time not lasting longer than 6-8 hours). Powdered medications are packaged in vials and must be constituted (dissolved in a suitable liquid) before being used in a solution. SVPs in the form of ampules, vials, or prefilled syringes are usually added to a minibag or an LVP, but they can also be used as the final container. A solution to which such an additive has been added to a minibag or LVP is referred to as an admixture. SVPs are the backbone of basic IV compounding for hundreds of medicines that require additional dilution. Hospitals, healthcare systems, and ambulatory care infusion facilities continue to experience intermittent shortages of small-volume parenteral solutions (SVPs).
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that United States & German Players will contribute the maximum growth to Global Small Volume Injectable market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Allergan Inc. (Ireland), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Bayer AG (Germany), Teva Pharmaceuticals (Israel), Pfizer Inc. (United States), Becton, Dickinson and Company (United States), Eli Lilly and Company (United States), Novartis AG (Switzerland) and Baxter International, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Schott AG (Germany), Gerresheimer (Germany), Ypsomed (Switzerland), B. Braun Melsungen (Germany) and Others.
Segmentation Overview
AMA Research has segmented the market of Global Small Volume Injectable market by , Application (Local Anesthetics, Vaccines and Others) and Region.
On the basis of geography, the market of Small Volume Injectable has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Hospitals will boost the Small Volume Injectable market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Package, the sub-segment i.e. Ampules will boost the Small Volume Injectable market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Rising Geriatric Population
Market Growth Drivers:
Prevalence of Chronic Infectious Diseases and High Investment in Health Care R&D
Challenges:
Fierce Competitive Pressure
Restraints:
Lack of Skilled Professionals and High Initial Investment
Opportunities:
Growing Healthcare Infrastructure Across Emerging Regions
Market Leaders and their expansionary development strategies
In May 2021, Dr. Reddy's Laboratories Launched Ertapenem for Injection in the U.S. Market. The New Injection, 1 g/vial, is a Therapeutically Equivalent Generic Version of INVANZ (Ertapenem for Injection), 1 G/Vial, Approved by The US Food and Drug Administration (USFDA).
In May 2020, Tolmar Pharmaceuticals, Inc Received U.S. Food and Drug Administration (FDA) Approval to its New Drug Application for FENSOLVI (leuprolide acetate) For Injectable Suspension for The Treatment of Pediatric Patients Two Years of Age and Older with Central Precocious Puberty (CPP).
Key Target Audience
Small Volume Injectable Manufactures, New Entrants and Investors, Small Volume Injectable Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.